Heute wieder zusteigen bitte!!!! - 500 Beiträge pro Seite

[bernimaus]

So Leute, heute wieder eine kurze Chance zum Aufspringen auf den rasenden Zug... Peptech aus Australien genehmigt sich heute - nach dem Hoch von 0,64€ gestern Abend - eine kleine Pause zum Luftholen.

Also alles Einsteigen bitte, Türen schliessen und die Luft anhalten...

WKN 880056.

Schöne Grüße an alle Peppies! Vor allem an Tea und Sharia, die sich gestern mit mir über die 0.64 gefreut haben.

[Tea]

Danke Bernimaus,
übrigens was hälst Du von der neuen Nachricht ???

Gruß Tea.

[bernimaus]

Hallo Tea, auf die schnelle klingt es sehr gut. Aber ich bin noch am Übersetzen, Oh Gott - mein Schulenglisch ist echt weit weg...

Derweil hab ich die letzte Meldung hier mal reinkopiert, für alle die wissen wollen, wo sie ihre Euros reistecken sollten!

So, was jetzt folgt ist von der Homepage: www.peptech.com:

********************************************************************

Result of European Patent Office Hearing


Document date: Wed 06 Sep 2000 Released time: Wed 06 Sep 2000 11:04:25
Document No: 216935 Document part: A
Market Flag: Y
Classification: Other
PEPTECH LIMITED 2000-09-06 ASX-SIGNAL-G

HOMEX - Sydney

+++++++++++++++++++++++++
Peptech was successful at the EPO hearing in Munich on 5 September
2000.

BASF withdrew their request for restitutio and thereby effectively
withdrew their right to appeal against the grant by the EPO of
Peptech`s European patent for TNF Binding Ligands. Consequently
Peptech`s European patent for TNF Binding Ligands is now granted
unopposed.

I have, in my second update, informed the market that BASF has,
subsequent to the granting by the EPO of the Company`s TNF Binding
Ligands patent, opposed the grant. BASF`s opposition was rejected by
the EPO. BASF lodged their notice of appeal against the decision but
filed the grounds of appeal after the expiration of the time limit
imposed by the EPO rules. Consequently, BASF was asked to submit
reasons for their late submission before their appeal status could be
restored by the EPO. The EPO had indicated to BASF and the Company,
that their preliminary view was that the reasons given by BASF were
not adequate, but that BASF would be given an opportunity on 5
September 2000 to overturn the EPO`s preliminary view.

Although BASF was invited to submit oral arguments that the
previously held view of the EPO that BASF`s restitution grounds were
inadequate was wrong, they instead withdrew their request for
restitutio. The effect of this withdrawal is that BASF`s appeal
against the EPO`s original grant to Peptech of the patent has now
effectively ended and consequently Peptech`s European patent is now
granted unopposed.

BASF and other pharmaceutical companies have invested substantial
amounts in the development of their TNF therapeutics that Peptech
contends fall within the scope of Peptech`s patent. Whilst drugs
manufactured by Immunex and Centocor are already available in the
market, BASF and Celltech Chiroscience have made it known that they
are proposing to register their respective drugs next year. We
believe that it would be in the interest of all these pharmaceutical
companies and Peptech, that agreements be reached to license the
Peptech patent as soon as possible. To this end, it is envisaged that
dialogue with these pharmaceutical Companies will continue within the
next couple of weeks.

We are now entering an exciting phase in Peptech`s development. The
decision in Munich yesterday substantially advances the Company`s
case in ensuring worldwide commercialisation rights to products using
the Company`s patent. In my earlier update, I indicated that
worldwide sales of TNF therapeutics that fall within the scope of
Peptech`s patents exceed US$2 billion per annum. Attempts will now
be made to ensure that Peptech`s commercial rights, in relation to
its patents, will be strenuously enforced.


S Kwik
MANAGING DIRECTOR

[Tea]

Hallo Bernimaus,
kleiner Tipp:onlinetranslation.de !!!
Übersetzt zwar nicht Sinngemäß, dafür aber ganze Seiten.

Tea.